Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea

Pharmacotherapy
Sukhyang Lee, Sukhyang Lee

Abstract

Patients with coronary heart disease (CHD) frequently use the combination of a statin and renin-angiotensin-aldosterone system (RAAS) blocker, an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB), to control lipid levels and blood pressure, respectively, and the use of ARBs is increasing in Korean patients. Few studies are available, however, that have compared combination therapy with statin-ACEIs versus statin-ARBs. The objective of this study was to evaluate whether ARBs are associated with a reduced risk of major adverse cardiovascular and cerebrovascular events (MACCEs) compared with ACEIs when used in combination with statins in patients with established CHD. Population-based retrospective cohort study. Korean National Health Insurance Service-National Sample Cohort database. A total of 6577 adults who started statin-RAAS blocker combination therapy (1870 in the statin-ACEI cohort and 4707 in the statin-ARB cohort) after being diagnosed with CHD between January 2003 and December 2013 were included. Of these, 3676 propensity score-matched patients (1838 in the statin-ACEI cohort and 1838 in the statin-ARB cohort) were included in the final analyses. The primary outcome was MACCE (major...Continue Reading

References

Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Nov 30, 2002·Lancet·James ShepherdUNKNOWN PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Edmund LeeDennis Schneck
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
Mar 4, 2006·Clinical Pharmacology and Therapeutics·Soo-Chin LeeBoon-Cher Goh
Jan 31, 2007·The American Journal of Cardiology·James K Liao
Apr 4, 2007·The American Journal of Medicine·Barry J Materson
Apr 7, 2007·Journal of Hypertension·UNKNOWN Blood Pressure Lowering Treatment Trialists' CollaborationS MacMahon
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Apr 4, 2012·Indian Journal of Endocrinology and Metabolism·Jamshed J DalalAshish Gulati
Jan 10, 2014·Circulation Journal : Official Journal of the Japanese Circulation Society·Hae-Young LeeKwang Kon Koh
Jul 15, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pil Sang SongUNKNOWN Other Korean Working Group in Myocardial Infarction (KorMI) Registry Investigators
Dec 25, 2015·The Korean Journal of Internal Medicine·Jang Hoon LeeUNKNOWN Korea Acute Myocardial Infarction Registry Investigators
Jan 23, 2016·Journal of Clinical Pharmacy and Therapeutics·H-S KimI Y Choi
Feb 15, 2017·BMC Health Services Research·Karen L TangDoreen M Rabi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.